Lifestyle · Article

Bioimpedance Scale or DEXA: How to Tell If You're Losing Fat or Muscle

What a bioimpedance scale and a DEXA scan actually measure, how far off studies found them, how to use a scale, what GLP-1 trials measured, and waist size.

Written by
Published
Next review
Sources
9 primary and 10 supporting

No clinical review. No advertising from drug companies and no affiliate links.How we work

A bioimpedance scale weighs you accurately, but it doesn’t measure fat or muscle: it calculates them with a formula from the electrical current that passes through your body. In studies that compare these scales with DEXA, the error for any one person can be several kilograms14. DEXA (or DXA, a whole-body scan) is the clinical reference, but it doesn’t see muscle on its own either. If you take a GLP-1 medication and worry about losing muscle, the most useful signals are the scale’s trend under the same conditions, your waist and, above all, your strength.

In 30 seconds

  • At a Paris hospital, three smart scales got weight right (median error of 0 to 0.3 kg, or 0 to 0.7 lb) but underestimated fat by a median of 2.2 to 4.4 kg (4.9 to 9.7 lb) compared with DEXA[1].
  • Across 15 bioimpedance devices, repeat readings were nearly identical, but the average error ranged from −3.5 to +11.7 body fat percentage points depending on the model[3].
  • STEP 1, semaglutide: of 13.6 kg (30 lb) lost, 8.3 kg (18.3 lb) was fat and 5.3 kg (11.7 lb) lean mass (38%)[16]. SURMOUNT-1, tirzepatide: about 75% fat and 25% lean mass[14].
  • Lean mass isn’t just muscle: it also includes organs, fluids and the water inside fat tissue[15].
  • Waist (WHO): increased risk above 94 cm (37 in) in men and 80 cm (31.5 in) in women; substantially increased above 102 cm (40 in) and 88 cm (34.6 in)[18].

Why muscle is a concern on these medications, and how to protect it, is covered in protein and muscle on GLP-1 medications. Here I focus on how to measure it.

What each method measures

Method What it actually measures What it calculates Where
Bioimpedance scale Weight and resistance to a weak electrical current Fat, “muscle”, water Home, pharmacy, gym
Whole-body DEXA Bone, fat and lean mass by region (arms, legs, trunk) Derived indexes, such as lean mass of the arms and legs Hospital or imaging center
Skinfolds Thickness of the fat under the skin at several sites Body fat percentage, with equations Clinic, with trained staff
Tape measure Waist circumference Nothing: used as is Home

The bioimpedance scale

The scale sends a weak current through you and measures the body’s resistance, which depends mostly on water. The National Institutes of Health (NIH) technology assessment conference on bioimpedance concluded that it gives a reliable estimate of total body water under most conditions[6]. Fat and muscle are then calculated with an equation. The European consensus on sarcopenia, EWGSOP2, puts it plainly: bioimpedance doesn’t measure muscle mass directly, it estimates it, and the equation is calibrated against DEXA in a specific population[17]. If your body isn’t like that population’s, the estimate drifts.

According to Frija-Masson, most smart scales measure foot to foot only; other devices, like some at pharmacies or gyms, add hand electrodes[1].

The 2025 advisory on GLP-1 therapy from four US obesity, nutrition and lifestyle medicine societies notes one limit: people with a pacemaker, an implantable cardioverter defibrillator or another electronic medical implant cannot use a bioimpedance machine[16].

DEXA

It’s a scan with X-rays at two energies, done lying down; a 2021 review estimates 10 to 15 minutes per person[12]. According to the International Society for Clinical Densitometry (ISCD), the report should include, among other data, bone density, total mass, total lean mass, total fat mass and body fat percentage. It may add visceral fat or the lean mass of the arms and legs[11]. The dose from the most widely used machines is about 4 to 5 microsieverts, less than one day of natural background radiation in the United Kingdom (5 to 8 microsieverts), according to the same review[12].

It isn’t perfect either. EWGSOP2 warns that machines from different brands don’t give consistent results and that hydration affects DEXA too[17]. The 2021 review notes that the scanning area is about 195 cm (6 ft 5 in) long: people who are very tall or very broad may not fit entirely[12]. And against a four-compartment reference method, Minderico (2008) found that DEXA overestimated the fat lost by 48 women who lost an average of 3.3 kg (7.3 lb). The authors concluded that none of the clinical methods they tested was accurate enough to track those changes and that they shouldn’t be used interchangeably[5].

Skinfolds and tape measure

According to the 2021 review, skinfolds are the method least affected by meals or hydration, but they depend heavily on the skill of the person measuring. And because the equations that turn skinfolds into a body fat percentage disagree, the authors prefer comparing the sum of millimeters[12].

A tape measure is the cheapest option and has published risk cut-offs (more below). The mirror, photos in the same light or how a pair of pants fits have no studies behind them, but they’re free and don’t depend on any formula.

Is a bioimpedance scale accurate? What the studies say

Study Who Devices Result against the reference
Frija-Masson, 2021[1] About 50 patients per scale at a Paris hospital; median BMI 28 to 31 3 home smart scales Weight: median error 0 to 0.3 kg (0 to 0.7 lb). Fat: underestimated, median 2.2 to 4.4 kg (4.9 to 9.7 lb). “Muscle”: −6.6 to +4.5 kg (−14.6 to +9.9 lb) depending on the scale
Bosy-Westphal, 2008[2] 106 adults, mean BMI 25.8 3 foot-to-foot and 1 hand-and-foot 95% limits of individual differences: up to −14.5 to +8.6 body fat points for foot-to-foot; −6.6 to +4.6 for hand-and-foot
Siedler, 2023[3] 73 healthy adults aged 19 to 50 14 consumer and 1 research device Average error −3.5 to +11.7 body fat points depending on the device; for changes over 12 to 16 weeks (37 people), −0.4 to +1.3
Nickerson, 2020[4] 50 adults with obesity, mean BMI 36 2 professional hand-and-foot devices Error up to about ±5 body fat points or ±5 kg (±11 lb) of fat-free mass; not acceptable for individual estimates

Frija-Masson concluded that smart scales aren’t accurate for body composition and shouldn’t replace DEXA[1]. Bosy-Westphal, that foot-to-foot scales work for studying groups and that, for an individual, a device with hand and foot electrodes is preferable[2]. Siedler, that some models (especially eight-electrode and certain foot-to-foot devices) may be useful for tracking change over time, where they performed best[3].

Two more caveats:

  • Repeatable isn’t accurate. In Siedler, measuring twice in a row gave almost the same number (precision error of 0 to 0.49 points)[3]. A scale that repeats a number isn’t necessarily giving the right one.
  • With obesity or dehydration, more caution. The ESPEN guidelines, from the European society for clinical nutrition, don’t recommend routine bioimpedance at extremes of BMI or with abnormal hydration. They consider tracking change with it possible at a BMI of 16 to 34 without abnormal hydration, and even then with caution[7].

What moves the reading from day to day

The NIH conference listed what affects the measurement: body position, hydration, food and drink, air and skin temperature, and recent physical activity. It concluded that reliable bioimpedance requires controlling these variables[6]. The specific studies:

  • Meals. In 18 adults measured 18 times over 24 hours, impedance dropped for 2 to 4 hours after each meal, and the effect added up over the day. According to the abstract, calculated body fat percentage varied by 8.8% in women and 9.9% in men between the highest and lowest readings of the day, without specifying whether these are body fat points or a relative change (Slinde, 2001)[8].
  • Eating or drinking right before. In 55 adults on a foot-to-foot scale, a meal or an electrolyte drink shifted body fat percentage by about one point over the next two hours (Androutsos, 2015). The authors considered the effect small[9].
  • Menstrual cycle. In 25 women measured daily for one cycle, resistance and estimated fat-free mass changed between phases, though body fat percentage didn’t. Small weight changes from water, linked to salt intake, explained part of the error (Gleichauf, 1989)[10].

On a GLP-1 medication there’s one more factor: if you’ve had vomiting or diarrhea, your hydration has changed, and so has the reading.

How to use the scale so it’s worth something

These rules follow from the above:

  • Same conditions every time: when you get up, after using the bathroom and before eating or drinking.
  • Never right after a workout, or after a day of vomiting or diarrhea.
  • If you menstruate, compare readings from the same phase of your cycle.
  • Look at the trend over weeks, not one day’s number.
  • Don’t mix devices. According to EWGSOP2, muscle estimates vary with the brand of device[17]; your home scale and the gym’s aren’t comparable.

What the semaglutide and tirzepatide trials measured with DEXA

The two main trials measured body composition with DEXA in a subgroup of participants1314. The STEP 1 kilograms are those reported in the 2025 advisory[16].

Trial Who Weight Fat mass Lean mass Share of weight lost that was lean mass
STEP 1, semaglutide 2.4 mg, 68 weeks (trial summary) 140 adults without diabetes −15.0% (placebo: −3.6%) −19.3% −9.7% 38% (5.3 of 13.6 kg, or 11.7 of 30 lb)
SURMOUNT-1, tirzepatide, 72 weeks (substudy summary) 160 adults without diabetes −21.3% (placebo: −5.3%) −33.9% −10.9% About 25%, same as placebo

In STEP 1, lean mass fell in kilograms, but its share of the body rose 3.0 points because much more fat was lost[13]. The Neeland review (2024) notes that figures vary across GLP-1 studies: in some, lean mass was 40% to 60% of the weight lost; in others, 15% or less[15].

Lean mass isn’t the same as muscle. Neeland explains that besides muscle it includes organs, fluids and the water inside fat tissue[15]. The 2025 advisory estimates that muscle is about half of lean mass: in STEP 1, around 20% of the weight lost[16].

When a DEXA scan is worth it and how to ask for one

The 2025 advisory recommends assessing strength, physical function and, where possible, muscle mass (by bioimpedance, DEXA or other methods) when treatment starts. For follow-up, it suggests DEXA every year or every two years. It also warns that many imaging sites with DEXA don’t run the body composition analysis[16]. EWGSOP2, for its part, advises DEXA in clinical practice to confirm sarcopenia (loss of muscle mass and strength) once strength has tested low[17].

If you think it might help you, bring it up at your next appointment. Three useful questions:

  • Do my age, strength or other conditions justify measuring body composition?
  • If so, can it be a whole-body DEXA with body composition analysis, not just a bone scan?
  • If I repeat it, can it be on the same machine? Results from different brands aren’t comparable[17].

You can write them down in the doctor-visit checklist.

Waist size: the cheap measure with published cut-offs

The WHO expert consultation lists these cut-offs for risk of metabolic complications, based mostly on studies in people of European origin[18]:

Men Women
Increased risk (WHO) over 94 cm (37 in) over 80 cm (31.5 in)
Substantially increased risk (WHO) over 102 cm (40 in) over 88 cm (34.6 in)
Central and South American populations (IDF)[19] 90 cm (35.4 in) or more 80 cm (31.5 in) or more

The International Diabetes Federation (IDF) uses cut-offs by ethnic group. For people of Central and South American origin, it provisionally applies the South Asian values until more specific data are available. For people of European origin, 94 and 80 cm. It also notes that in the USA the higher values of 102 cm (40 in) for men and 88 cm (34.6 in) for women are likely to remain in clinical use[19].

The WHO describes how to measure: standing, feet close together, wearing little clothing, midway between the lowest rib and the top of the hip bone. Keep the tape parallel to the floor and snug without squeezing, and read it at the end of a normal breath out. Measure twice and, if the two readings are within 1 cm (0.4 in), take the average[18]. For tracking yourself, what matters is always measuring at the same spot. In what BMI measures and what it misses I explain why waist size complements BMI.

Signs you may be losing muscle, and what protects it

EWGSOP2 treats low strength as the main feature of sarcopenia, ahead of mass. These are the signs it lists as reasons to look for it: falls, feeling weak, walking more slowly, difficulty getting up from a chair, or losing weight or muscle. And these are its strength cut-offs, designed mainly for older adults[17]:

  • Rising from a chair five times without using your arms: more than 15 seconds indicates low leg strength.
  • Grip strength, measured with a dynamometer: under 27 kg (about 60 lb) in men and 16 kg (about 35 lb) in women.

The 2025 advisory adds that these tests work better in older adults and may be less able to detect change in younger people[16]. If you train, logging what you lift, or how many times you can stand up from a chair in 30 seconds (a variant of the test), gives you a signal no scale measures. If you notice any of the signs, talk to your doctor.

Two things together protect muscle. Enough protein: targets of 1.2 to 1.6 g per kg a day (about 0.55 to 0.73 g per lb) have been proposed during active weight loss, the 2025 advisory notes[16], and you can work out your number with the protein calculator. And strength training: the 2025 advisory proposes at least three sessions a week and warns that more protein without strength training is likely not enough[16]. The details are in protein and muscle on GLP-1 medications.

Frequently asked questions

Is a bioimpedance scale accurate?

For weight, yes. For one person’s fat and muscle, not very: in studies, the error reached several kilograms or more than 10 body fat points depending on the model123. It’s more useful for seeing a trend, always measuring under the same conditions.

How much muscle do you lose on Ozempic?

On semaglutide 2.4 mg weekly, the Wegovy dose, lean mass was 38% of the weight lost in the STEP 1 subgroup (5.3 of 13.6 kg, or 11.7 of 30 lb)1316. On tirzepatide, about 25% in SURMOUNT-1[14]. Not all of it is muscle: the 2025 advisory estimates muscle is about half[16].

My scale says I’m losing muscle. Is it true?

The scale can’t confirm it. Some lean mass is lost with weight loss, but the scale’s muscle estimate is off by several kilograms and shifts with food and hydration189. Watch your strength and the trend over several weeks.

Where can I get a DEXA scan?

Hospitals and imaging centers with a DEXA machine do them; ask your doctor whether it’s appropriate in your case. Ask for a whole-body scan with body composition analysis: according to the 2025 advisory, many sites with DEXA don’t offer it[16].

Which is better, the scale or a tape measure?

They measure different things. Your waist doesn’t tell you how much muscle you have, but it’s cheap, easy to repeat and has risk cut-offs published by the WHO and the IDF1819. The scale estimates fat and muscle, with a large error. Together, and with your strength, they give a fuller picture.

Sources

Sources consulted for this article, with the access date.

  1. Other sourceJMIR mHealth and uHealth (PubMed Central).Frija-Masson J, et al. Accuracy of Smart Scales on Weight and Body Composition: Observational Study. JMIR Mhealth Uhealth. 2021;9(4):e22487.accessed .
  2. Other sourceObesity Facts (PubMed Central).Bosy-Westphal A, et al. Accuracy of bioelectrical impedance consumer devices for measurement of body composition in comparison to whole body magnetic resonance imaging and dual X-ray absorptiometry. Obes Facts. 2008;1(6):319-324.accessed .
  3. Other sourceBritish Journal of Nutrition (PubMed Central).Siedler MR, et al. Assessing the reliability and cross-sectional and longitudinal validity of fifteen bioelectrical impedance analysis devices. Br J Nutr. 2023;130(5):827-840.accessed .
  4. Other sourceJournal of Clinical Densitometry.Nickerson BS, et al. Agreement Between 2 Segmental Bioimpedance Devices, BOD POD, and DXA in Obese Adults. J Clin Densitom. 2020;23(1):138-148.accessed .
  5. Other sourceBritish Journal of Nutrition.Minderico CS, et al. Usefulness of different techniques for measuring body composition changes during weight loss in overweight and obese women. Br J Nutr. 2008;99(2):432-441.accessed .
  6. Clinical guidelineAmerican Journal of Clinical Nutrition (NIH).Bioelectrical impedance analysis in body composition measurement: National Institutes of Health Technology Assessment Conference Statement. Am J Clin Nutr. 1996;64(3 Suppl):524S-532S.accessed .
  7. Clinical guidelineClinical Nutrition (ESPEN).Kyle UG, et al. Bioelectrical impedance analysis, part II: utilization in clinical practice (ESPEN). Clin Nutr. 2004;23(6):1430-1453.accessed .
  8. Other sourceAmerican Journal of Clinical Nutrition.Slinde F, Rossander-Hulthén L. Bioelectrical impedance: effect of 3 identical meals on diurnal impedance variation and calculation of body composition. Am J Clin Nutr. 2001;74(4):474-478.accessed .
  9. Other sourceJournal of Human Nutrition and Dietetics.Androutsos O, et al. Impact of eating and drinking on body composition measurements by bioelectrical impedance. J Hum Nutr Diet. 2015;28(2):165-171.accessed .
  10. Other sourceAmerican Journal of Clinical Nutrition.Gleichauf CN, Roe DA. The menstrual cycle's effect on the reliability of bioimpedance measurements for assessing body composition. Am J Clin Nutr. 1989;50(5):903-907.accessed .
  11. Clinical guidelineInternational Society for Clinical Densitometry (ISCD).Petak S, et al. The Official Positions of the International Society for Clinical Densitometry: body composition analysis reporting. J Clin Densitom. 2013;16(4):508-519.accessed .
  12. Other sourceNutrients (PubMed Central).Kasper AM, et al. Come Back Skinfolds, All Is Forgiven: A Narrative Review of the Efficacy of Common Body Composition Methods in Applied Sports Practice. Nutrients. 2021;13(4):1075.accessed .
  13. Clinical trialJournal of the Endocrine Society (PubMed Central).Wilding J, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. J Endocr Soc. 2021;5(Suppl 1):A16-A17.accessed .
  14. Clinical trialDiabetes, Obesity and Metabolism.Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729.accessed .
  15. Other sourceDiabetes, Obesity and Metabolism.Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(Suppl 4):16-27.accessed .
  16. Clinical guidelineObesity (The Obesity Society, Wiley).Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from ACLM, ASN, OMA and The Obesity Society. Obesity. 2025;33(8):1475-1503.accessed .
  17. Clinical guidelineAge and Ageing (PubMed Central).Cruz-Jentoft AJ, et al. Sarcopenia: revised European consensus on definition and diagnosis (EWGSOP2). Age Ageing. 2019;48(1):16-31.accessed .
  18. Clinical guidelineWorld Health Organization.Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8-11 December 2008 (annex A, table A1).accessed .
  19. Clinical guidelineInternational Diabetes Federation (IDF).The IDF consensus worldwide definition of the metabolic syndrome (2006), table 2.accessed .